Profile for Japan Patent: 3567162

« Back to Dashboard

US Patent Family Members and Approved Drugs for Japan Patent: 3567162

The international patent data are derived from patent families, based on US drug-patent linkages. Full freedom-to-operate should be independently confirmed.

Glossary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial
US Patent Number	US Expiration Date	US Applicant	US Tradename	Generic Name
➤ Sign Up	Aug 27, 2026	Gilead Sciences Inc	GENVOYA	cobicistat; elvitegravir; emtricitabine; tenofovir alafenamide fumarate
➤ Sign Up	Aug 27, 2026	Gilead Sciences Inc	STRIBILD	cobicistat; elvitegravir; emtricitabine; tenofovir disoproxil fumarate
➤ Sign Up	Aug 27, 2026	Gilead Sciences Inc	VITEKTA	elvitegravir
US Patent Number	US Expiration Date	US Applicant	US Tradename	Generic Name

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

By using our website you are consenting to our use of cookies in accordance with our privacy policy.